Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Clin Cancer Res. 2017 Nov 1;23(21):6468–6477. doi: 10.1158/1078-0432.CCR-17-0615

Figure 2. PDX responses to approved therapies.

Figure 2

The response of PDXs is shown on the left. PDXs were treated with paclitaxel, doxorubicin, carboplatin, eribulin or gemcitabine weekly for up to 28 days. Median response is shown as defined in the key. All models defined as regressive had 100% of engraftments regress. No progressive models showed interval regression. TNBCtype shown in center; the subtypes in parenthesis are based on the revised TNBCType-4 scheme. The neoadjuvant therapy that the patient received is shown on the right. Radiographic responses were color-coded: red: progression, orange: stable disease, and green: partial response. PTX-Paclitaxel; T-paclitaxel (Taxol), Traz-trastuzumab; FEC-fluorouracil+epirubicin+cyclophosphamide; FAC-Fluorouracil+doxorubicin (Adriamycin)+cyclophosphamide;TAC-docetaxel (Taxotere)+ doxorubicin + cyclophosphamide.